September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Advanced Squamous NSCLC Survival Improved With Chemoimmunotherapy Regardless of PD-L1 Expression
July 20th 2022During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.
Read More
Immunotherapies Offer Alternatives to Chemotherapy for PD-L1–High Lung Cancer
June 27th 2022During a Targeted Oncology live virtual event, Martin F. Dietrich, MD, PhD, discussed data from 3 trials of immunotherapy agents for patients with non–small cell lung cancer with high PD-L1 expression.
Read More
Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC
June 27th 2022In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.
Read More
Tazemetostat Results Signal the Utility of Biomarker-Driven Therapy for BAP1-Inactivated MPM
June 24th 2022Results from a study of tazemetostat in patients with BAP1-inactivated malignant pleural mesothelioma show the feasibility of molecularly-stratified therapy for patients with relapsed or refractory disease.
Read More
Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC
June 22nd 2022During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.
Read More
Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLC
June 13th 2022During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.
Read More
FDA Accepts sBLA for Pembrolizumab in Stage IB, II, or III NSCLC
June 13th 2022A new supplemental biologics license application has been accepted by the FDA for pembrolizumab as treatment of patients with 1B (≥4 centimeters), 2, or 3 non-small cell lung cancer after complete surgical resection.
Read More
KEYNOTE-799 Results Reveal Durable Responses in Previously Untreated Stage III NSCLC
June 9th 2022In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.
Read More
Brain Metastasis in Patients With NSCLC Correlates With Enrichment of CDKN2A/B and EGFR Mutations
June 6th 2022Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.
Read More
Patients with NSCLC Experience Improved DFS with Pembrolizumab After Surgery
June 6th 2022Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.
Read More
Pembrolizumab With Ramucirumab Boosts Survival Vs SOC in ICI-Resistant NSCLC
June 3rd 2022The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.
Read More
Sugemalimab Demonstrates Clinically Meaningful PFS Boost in Unresectable NSCLC
May 26th 2022GEMSTONE-301 showed sugemalimab to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival in patients with unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
Read More
Low Molecular Testing Rate, Disparities in Care Shown in Real-World Study of NSCLC in Latin America
May 24th 2022Findings from a retrospective real world study conducted in patients with EGFR-mutated, stage IV non–small cell lung cancer from 4 Latin American countries showed a 66% frequency rate in molecular testing and a frequency of EGFR mutations of 22% overall.
Read More